Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals
- Authors
- Yim, Sun Young; Lee, Jeong-Hoon; Ahn, Hongkeun; Kim, Seung Up; Kim, Sang Gyune; Kim, Young Seok; Kim, Jeong Han; Choe, Won Hyeok; Kim, Tae Yeob; Jung, Young Kul; Suh, Sang Jun; Suk, Ki Tae; An, Hyunggin; Yim, Hyung Joon; Seo, Yeon Seok; Um, Soon Ho
- Issue Date
- 9월-2016
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Keywords
- chronic hepatitis B; liver-related mortality; liver cirrhosis; subclinical ascites
- Citation
- JOURNAL OF CLINICAL GASTROENTEROLOGY, v.50, no.8, pp.676 - 685
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL GASTROENTEROLOGY
- Volume
- 50
- Number
- 8
- Start Page
- 676
- End Page
- 685
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/87698
- DOI
- 10.1097/MCG.0000000000000529
- ISSN
- 0192-0790
- Abstract
- Background and Aims: This study evaluated the clinical significance of subclinical ascites in patients with hepatitis B virus-related cirrhosis treated with lamivudine (LMV) or entecavir (ETV). Methods: This multicenter retrospective study involved 8 hospitals. Patients were classified by degree of ascites: (1) no ascites (no ascites on imaging, no diuretics), (2) subclinical ascites (small amount of ascites on imaging, no diuretics), and (3) clinical ascites (moderate to severe ascites or diuretics). Results: Out of 501 patients, 336 (68%), 51 (10%), and 114 (23%) patients were classified as no-ascites, subclinical ascites, and clinical ascites, respectively. In all, 100 (20%) and 401 (80%) were treated with LMV and ETV, respectively. Over 58+/-24 months of follow-up, 105 patients (21%) developed hepatocellular carcinoma. The cumulative incidence of hepatocellular carcinoma did not differ between LMV-treated and ETV-treated patients (P=0.61); it was higher in the clinical-ascites group than the no-ascites (P=0.054) and subclinical-ascites (P=0.03) groups, but it was comparable between the latter 2 (P=0.225). Forty-five patients (9%) died during follow-up. Survival was significantly shorter in the clinical-ascites group than the other 2 (both P<0.005), but it was comparable between no-ascites and subclinical-ascites groups (P=0.444). Multivariate analysis showed that mortality was significantly associated with prothrombin time [hazard ratio (HR)=2.42; 95% confidence interval (CI), 1.59-3.70], serum albumin (HR=0.54; 95% CI, 0.29-0.99), and presence of clinical ascites (HR=3.58; 95% CI, 1.54-8.30). Conclusions: Subclinical ascites did not affect prognosis in patients with hepatitis B virus-related cirrhosis receiving antiviral treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.